PS
RGNX icon

Principal Securities’s Regenxbio RGNX Stock Holding History

Principal Securities’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59
Closed -$569 – 3046
2025
Q3 		$569 Hold
59
– – ﹤0.01% 3518
2025
Q2 		$484 Sell
59
-130
-69% -$1.09K ﹤0.01% 3485
2025
Q1 		$1.46K Hold
189
– – ﹤0.01% 3124
2024
Q4 		$1.46K Hold
189
– – ﹤0.01% 3118
2024
Q3 		$1.98K Hold
189
– – ﹤0.01% 2956
2024
Q2 		$2.21K Hold
189
– – ﹤0.01% 2888
2024
Q1 		$3.98K Buy
189
+130
+220% +$2.31K ﹤0.01% 2678
2023
Q4 		$1.06K Buy
+59
New +$1.04K ﹤0.01% 2944

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Principal Securities's RGNX Position: Q4 2025 in Review

Principal Securities sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 59 shares — an estimated $569 sold.

Principal Securities first reported a position in RGNX in Q4 2023 and held it in 8 quarters. The position peaked at $3.98K in Q1 2024. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

  • Principal Securities reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 59 Regenxbio shares in Q4 2025, an estimated $569.
  • Principal Securities first reported a position in Regenxbio in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Regenxbio position peaked at $3.98K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.